Pioneering founders, experienced leadership, and world-class advisors.

Leadership

Tim Lu, M.D., Ph.D.

Co-founder & CEO

Tim Lu, M.D., Ph.D.

Co-founder & CEO

Dr. Lu is a pioneer in synthetic biology and an Associate Professor at MIT. He received his MD/PhD from MIT and Harvard. He is a co-founder of Synlogic (NASDAQ: SYBX), Tango Therapeutics, Sample6, Eligo, BiomX, and Engine Biosciences. He has received the NIH New Innovator Award, the US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes, and others.

Philip Lee, Ph.D.

Co-founder & COO

Philip Lee, Ph.D.

Co-founder & COO

Dr. Lee is an entrepreneur and technology platform builder specializing in cellular systems. He has over a decade of life science leadership experience spanning product development, technical operations, marketing management, and innovation. He was the co-founder and CEO of CellASIC, which was acquired by Merck KGaA, and served as the former Head of Cell Culture Systems at Merck KGaA. He received his PhD in Bioengineering from UC Berkeley/UCSF and B.S. degrees in Chemical Engineering and Biology from the Massachusetts Institute of Technology. 

Curt Herberts, M.B.S.

Chief Financial Officer & Chief Business Officer

Curt Herberts, M.B.S.

Chief Financial Officer & Chief Business Officer

Curt Herberts joined our team in June 2018 and is responsible for leading the business operations, finance, corporate development, legal and people functions at Senti.  He is a seasoned business leader with experience in corporate strategy, finance, business development, commercialization and building high performing cell & gene therapy organizations. 

Prior to joining Senti, Curt was Senior Vice President and Chief Business Officer of a publicly traded genome editing company, Sangamo Therapeutics, where he led the business function and completed a number of global collaborations, including those with Shire rare disease, Biogen blood disorders, Pfizer rare disease, Pfizer neuroscience, and Gilead oncology. Curt has experience working across many different disease areas and advanced therapeutic modalities including in vivo gene therapy, ex vivo cell therapy and genome editing.

Mr. Herberts holds a B.A. degree in Human Biology from Stanford University and a Master of Business and Science (M.B.S.) from the Keck Graduate Institute of Applied Life Sciences.  Outside of work, Curt lives in the Bay Area peninsula and enjoys spending time with his wife and two kids, running on trails around his house, and snowboarding in the Sierras.
 

Gary Lee, Ph.D.​

Chief Scientific Officer

Gary Lee, Ph.D.​

Chief Scientific Officer

Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. As VP of Cell Therapy at Sangamo Therapeutics, Dr. Lee led the company’s programs around T-cell engineering, including CAR-T cell therapies for oncology applications (a platform recently licensed to Kite, a Gilead company) and T-cell therapies for HIV. Dr. Lee also served as the head of Sangamo’s immunology/Treg therapeutic pipeline. Dr. Lee received his B.S. in Chemical Engineering from California Institute of Technology and his Ph.D. in Chemical Engineering from U.C. Berkeley. 

Board of Directors

Tim Lu, M.D., Ph.D.

Co-founder & CEO, Senti

Tim Lu, M.D., Ph.D.

Co-founder & CEO, Senti

Dr. Lu is a pioneer in synthetic biology, and  an Associate Professor at MIT and received his MD/PhD from MIT and Harvard. He is a co-founder of Synlogic (NASDAQ: SYBX), Tango Therapeutics, Sample6, Eligo, BiomX, and Engine Biosciences. He has received the NIH New Innovator Award, the US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes, and others.

Ed Mathers

Partner, NEA

Ed Mathers

Partner, NEA

Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of multiple innovative biotechnology companies, including among others: Ra Pharmaceuticals (NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals (NASDAQ:RYTM), Synlogic (NASDAQ:SYBX), ObsEva (NASDAQ:OBSV), and Liquidia Technologies (NASDAQ: LQDA).

Previously he was a board member of Lumena (sold to Shire),  Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), MedImmune, LLC, and the Biotechnology Industry Organization (BIO).
Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. 

Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Alex Kolicich

Partner, 8VC

Alex Kolicich

Partner, 8VC

Alex Kolicich is a Founding General Partner of 8VC where he leads the firm's Bio-IT investments. Prior to joining 8VC, Alex was a Partner at Formation 8. Earlier in his career, Alex worked with Peter Thiel as a Principal at Mithril Capital Management, a growth-stage venture fund, where he helped lead investments in AppDirect, Adimab, C2FO and Helion Energy.

Prior to venture, he was an early engineer and product advisor at Clarium Capital, Palantir, and Google. While at Google Research, Alex worked on the launch of Google Street-Views and Google Checkout.
 

Laurent Fischer, M.D.

Serial Entrepreneur / CEO

Laurent Fischer, M.D.

Serial Entrepreneur / CEO

Dr. Fischer is currently senior vice president and head of the liver therapeutic area at Allergan, and is also a senior advisor on the Frazier Healthcare Partners’ Life Sciences team. Dr. Fischer has more than 20 years of drug development and commercialization experience in the biopharmaceutical industry. He was previously CEO of Tobira Therapeutics, which was acquired by Allergan for up to $1.7 billion in 2016.

Prior to Tobira, Dr. Fischer was chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy acquired for $150 million by Sillajen. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics. Dr. Fischer has also held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. He launched Sustiva®, the first once-daily anti-HIV and the 10th top-prescribed specialty drug, in 2015, and was involved in the launch of the first protease inhibitor in the United States. Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Scientific Advisory Board

Jim Collins, Ph.D.

Scientific Co-Founder

Jim Collins, Ph.D.

Scientific Co-Founder

Dr. Jim Collins is the Termeer Professor of Medical Engineering and Science in the Institute for Medical Engineering and Science as well as Professor of Biological Engineering at MIT. Jim is widely heralded as one of the founders of the field of synthetic biology, which applies engineering principles to the biological sciences in order to program novel gene circuits that can better control cellular behavior. Using this approach, Jim has pioneered innovative ways to detect and treat infections, and to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance.

In addition to his role as a faculty member at MIT, Jim is a Core Faculty member of the Wyss Institute at Harvard and an Institute Member of the Broad Institute of MIT and Harvard. Jim is a member of all three National Academies, and has been a Rhodes Scholar, a Macarthur Fellow, and a recipient of the NIH Pioneer Award.

In addition to co-founding Senti Biosciences, he is a co-founder of EnBiotix, Synlogic (NASDAQ: SYBX) and Sherlock Biosciences. Dr. Collins’ patented technologies have been licensed by over 25 biotech, pharma, and medical device companies. 

Wilson Wong, Ph.D.

Scientific Co-Founder

Wilson Wong, Ph.D.

Scientific Co-Founder

Dr. Wilson Wong is an Assistant Professor at Boston University. Wilson is an expert in immune cell engineering as well as metabolic pathway engineering.

After completing his B.S. degree in Chemical Engineering from UC Berkeley, Wilson conducted his Ph.D. thesis work in the laboratory of Prof. James Liao at UCLA and his postdoctoral studies in the laboratory of Prof. Wendell Lim at UCSF. Wilson’s research has been published in numerous high-impact journals including Nature, Nature Biotechnology, Cell, and PNAS.

Wilson has been recognized with multiple early academic career awards, including the NIH New Innovator Award, the ACS Synthetic Biology Young Investigator Award, and the NSF CAREER Award.

Larry Fong, M.D.

Clinical Advisor

Larry Fong, M.D.

Clinical Advisor

Lawrence Fong, M.D. is Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the UCSF. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. Dr. Fong obtained his BA from Columbia and MD from Stanford.He is an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation.

Martin Fussenegger, Ph.D.

Technical Advisor

Martin Fussenegger, Ph.D.

Technical Advisor

Dr. Fussenegger is a Professor of Biotechnology and Bioengineering at ETH Zurich. He is a recipient of the AIChE Bailey Award, the Merck Cell Culture Engineering Award, and the Gaden Award, among others. Dr. Fussenegger is a member of the American Institute for Medical and Biological Engineering (AIMBE), the Swiss Academy of Engineering Sciences (SATW), EMBO and the National Academy of Engineering (NAE) of the United States of America. He is a pioneer in therapeutic synthetic biology.

Ahmad (Mo) Khalil, Ph.D.

Technical Advisor

Ahmad (Mo) Khalil, Ph.D.

Technical Advisor

Ahmad (Mo) Khalil is Assistant Professor of Biomedical Engineering and the Associate Director of the Biological Design Center at Boston University, and a Visiting Scholar at the Wyss Institute at Harvard University. He is recipient of awards including the Presidential Early Career Award for Scientists and Engineers (PECASE), NIH New Innovator Award, NSF CAREER Award, DARPA Young Faculty Award, and a Hartwell Foundation Biomedical Research Award. He is an expert at mammalian synthetic biology.

Michael Andreeff, M.D., Ph. D.

Clinical Advisor

Michael Andreeff, M.D., Ph. D.

Clinical Advisor

Dr. Andreeff is a Professor of Medicine at MD Anderson, Leukemia & Stem Cell Transplantation. He is a pioneer of engineered cell therapies.

Our investors and partners

Our industry-leading partners share our vision to further enhance cell and gene therapies. 

View partnering